Utility of Adagrasib Plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic CRC

Nataliya Uboha, MD, PhD, of University of Wisconsin School of Medicine and Public Health, and Christopher Lieu, MD, of University of Colorado Medicine, highlight a recent analysis of the KRYSTAL-1 trial.

The study assessed the utility of adagrasib, a selective KRAS^G12C-inhibitor, in combination with cetuximab, an an anti-EGFR antibody, for the treatment of patients with KRAS^G12C-mutated metastatic colorectal cancer.